United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market (2025-2031) | Analysis, Growth, Forecast, Value, Segmentation, Size & Revenue, Industry, Trends, Outlook, Share, Companies, Competitive Landscape

Market Forecast By Drug Class (Endothelin Receptor Antagonists (ERAs), Vasodilators, Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Calcium Channel Blockers (CCBs), Prostacyclin and Prostacyclin Analogs), By Route of Administration (Inhalation, Injectable, Oral Administration), By End User (Hospitals, Clinics) And Competitive Landscape
Product Code: ETC9953117 Publication Date: Sep 2024 Updated Date: Aug 2025 Product Type: Market Research Report
Publisher: 6Wresearch Author: Dhaval Chaurasia No. of Pages: 75 No. of Figures: 35 No. of Tables: 20

Key Highlights of the Report:

  • United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Outlook
  • Market Size of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market, 2024
  • Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market, 2031
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Revenues & Volume for the Period 2021- 2031
  • United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Trend Evolution
  • United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Drivers and Challenges
  • United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Price Trends
  • United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Porter's Five Forces
  • United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Industry Life Cycle
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume By Drug Class for the Period 2021- 2031
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume By Endothelin Receptor Antagonists (ERAs) for the Period 2021- 2031
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume By Vasodilators for the Period 2021- 2031
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume By Phosphodiesterase-5 (PDE-5) Inhibitors for the Period 2021- 2031
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume By Soluble Guanylate Cyclase (sGC) Stimulators for the Period 2021- 2031
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume By Calcium Channel Blockers (CCBs) for the Period 2021- 2031
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume By Prostacyclin and Prostacyclin Analogs for the Period 2021- 2031
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume By Route of Administration for the Period 2021- 2031
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume By Inhalation for the Period 2021- 2031
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume By Injectable for the Period 2021- 2031
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume By Oral Administration for the Period 2021- 2031
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume By End User for the Period 2021- 2031
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume By Hospitals for the Period 2021- 2031
  • Historical Data and Forecast of United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume By Clinics for the Period 2021- 2031
  • United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Import Export Trade Statistics
  • Market Opportunity Assessment By Drug Class
  • Market Opportunity Assessment By Route of Administration
  • Market Opportunity Assessment By End User
  • United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Top Companies Market Share
  • United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Competitive Benchmarking By Technical and Operational Parameters
  • United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Company Profiles
  • United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Key Strategic Recommendations

Frequently Asked Questions About the Market Study (FAQs):

6Wresearch actively monitors the United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market and publishes its comprehensive annual report, highlighting emerging trends, growth drivers, revenue analysis, and forecast outlook. Our insights help businesses to make data-backed strategic decisions with ongoing market dynamics. Our analysts track relevent industries related to the United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market, allowing our clients with actionable intelligence and reliable forecasts tailored to emerging regional needs.
Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

1 Executive Summary

2 Introduction

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Overview

3.1 United Kingdom (UK) Country Macro Economic Indicators

3.2 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, 2021 & 2031F

3.3 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market - Industry Life Cycle

3.4 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market - Porter's Five Forces

3.5 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume Share, By Drug Class, 2021 & 2031F

3.6 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F

3.7 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume Share, By End User, 2021 & 2031F

4 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Dynamics

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of pulmonary arterial hypertension (PAH) in the UK

4.2.2 Growing awareness about PAH and its treatment options

4.2.3 Technological advancements in drug development for PAH

4.3 Market Restraints

4.3.1 High cost of PAH drugs leading to limited affordability

4.3.2 Stringent regulatory requirements for drug approval and market entry

5 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Trends

6 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market, By Types

6.1 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market, By Drug Class

6.1.1 Overview and Analysis

6.1.2 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Drug Class, 2021- 2031F

6.1.3 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Endothelin Receptor Antagonists (ERAs), 2021- 2031F

6.1.4 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Vasodilators, 2021- 2031F

6.1.5 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Phosphodiesterase-5 (PDE-5) Inhibitors, 2021- 2031F

6.1.6 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Soluble Guanylate Cyclase (sGC) Stimulators, 2021- 2031F

6.1.7 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Calcium Channel Blockers (CCBs), 2021- 2031F

6.1.8 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Prostacyclin and Prostacyclin Analogs, 2021- 2031F

6.2 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market, By Route of Administration

6.2.1 Overview and Analysis

6.2.2 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Inhalation, 2021- 2031F

6.2.3 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Injectable, 2021- 2031F

6.2.4 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Oral Administration, 2021- 2031F

6.3 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market, By End User

6.3.1 Overview and Analysis

6.3.2 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Hospitals, 2021- 2031F

6.3.3 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenues & Volume, By Clinics, 2021- 2031F

7 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Import-Export Trade Statistics

7.1 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Export to Major Countries

7.2 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Imports from Major Countries

8 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Key Performance Indicators

8.1 Patient adherence rate to PAH drug therapy

8.2 Number of PAH drug prescriptions filled

8.3 Rate of diagnosis of PAH cases in the UK

8.4 Research and development investment in PAH drug development

8.5 Number of healthcare providers specialized in treating PAH

9 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market - Opportunity Assessment

9.1 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Opportunity Assessment, By Drug Class, 2021 & 2031F

9.2 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Opportunity Assessment, By Route of Administration, 2021 & 2031F

9.3 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Opportunity Assessment, By End User, 2021 & 2031F

10 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market - Competitive Landscape

10.1 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Revenue Share, By Companies, 2024

10.2 United Kingdom (UK) Pulmonary Arterial Hypertension (PAH) Drugs Market Competitive Benchmarking, By Operating and Technical Parameters

11 Company Profiles

12 Recommendations

13 Disclaimer

Pricing
  • Single User License
    $ 1,995
  • Department License
    $ 2,400
  • Site License
    $ 3,120
  • Global License
    $ 3,795
6Wresearch Support

Any Query

Call: +91-11-4302-4305
Email us: sales@6wresearch.com
Any Query? Click Here

Thought Leadership and Analyst Meet

Our Clients

Airtel
Canon
Contec
HoneyWell
Kriloskar
Pwc Logo
Samsung
Tata Teleservices

Related Reports

Industry Events and Analyst Meet

Whitepaper

Read All